

# PHARMACEUTICAL QUALITY

**Richard Prince**

*Editor*

**PDA**

Bethesda, MD, USA

**DHI Publishing, LLC**

River Grove, IL, USA

[www.pda.org/bookstore](http://www.pda.org/bookstore)

10 9 8 7 6 5 4 3 2 1

**ISBN: 1-930114-61-3**

**Copyright © 2004 Richard Prince. All rights reserved.**

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Typeset in the United Kingdom by Dolffin. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book.

While every effort has been made by the publisher and the author to ensure the accuracy of the information contained in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the editors and authors and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.



**PDA**  
3 Bethesda Metro Center  
Suite 1500  
Bethesda, MD 20814  
United States  
301-986-0293



**Davis Healthcare International Publishing, LLC**  
2636 West Street  
River Grove  
IL 60171  
United States  
[www.DHIBooks.com](http://www.DHIBooks.com)

---

---

# CONTENTS

<b>Introduction</b>	<i>Richard Prince</i>	i
---------------------	-----------------------	---

## SECTION I : THE INTERNATIONAL LANDSCAPE OF QUALITY

<b>1. Global Disequilibrium of Quality</b>	<i>Lembit Rägo</i>	3
Introduction		3
WHO's Contribution to Medicines Quality		5
Pharmaceutical Gaps		7
Access Gap		7
Population/Consumption Gap		8
Human Resource Gap		9
Research and Development Gap		10
Quality Gap		10
Regulatory Capacity Gap		12
WHO's Response to Pharmaceutical Gaps: WHO Medicines Strategy		13
International Conference of Drug Regulatory Authorities (ICDRA)		13
Regional Harmonization initiatives: Setting Priorities		15
Remaining Challenges		16
Conclusions		17
References		18
About the Author		21
<b>2. Good Manufacturing Practices: An International Perspective</b>	<i>Michael H. Anisfeld</i>	23
Introduction		23
Drug Quality—Pharmacopeal Testing		24
The Advent of GMPs		26
GMPs: Codes, Directives, Guidelines, Points to Consider, or Regulations; and inspection severity		28
Drug Quality—GMP Implementation		30
The GMPs		36
Quality Management and the Qualified Person		39

Validation	40
Self-Inspection	42
Contract Manufacture and Contract Analysis	43
Future Trends—GMPs and Risk Assessment	43
Afterthought	45
About the Author	47
<b>3. Quality Management in the American Pharmaceutical Industry</b>	<b>49</b>
<i>Richard L. Friedman</i>	
Introduction	49
1. 'Global Quality Assurance'	50
2. Quality Foundation	51
Quality Leadership and Commitment	52
Trend Today, Improve Tomorrow	53
3. Good Science	53
4. Intended Use	55
5. People: Qualifications, Roles, Responsibilities	56
6. Reliable Laboratory	57
7. Suitability of Equipment, Facilities, and Associated Procedures	58
A Day in the Life: Minimizing Variability	58
Same way, Each Time	58
Quality—Business Synergy	59
8. Raw Material Quality and Surveillance	59
9. Batch Review and Release	61
10. Documentation	63
11. Effective Development and Process Validation	63
From Development to Commercialization	63
Lifecycle Progression: Monitoring Regular Production	65
12. 'Building Quality In' and the Willingness to Fix a Flawed Process	66
13. Effective Use of Risk Assessment	69
Advantages of Risk Assessment Methods	69
Quantity of Data Used to Assess Risk	69
Quality of Data: Adequacy of the Risk Assessment	70
Regulatory Concepts	71
14. Understanding Sources of Variability and Signals of Drift	73
Sources of Variability and Risk Mitigation	73
Why Drift Occurs	73
We've Always Done It That Way	75
Testing a Finished Product	75
Preventing Drift: Detect, Correct, Prevent	76
15. Awareness of the Link Between Safety, Efficacy, and Quality	76
16. The Quality Organization: Authority, Responsibility, and Accountability	78

Quality Management Metrics	79
17. Taking Action When Necessary	80
18. Internal Audit Program	80
19. Contracting and Outsourcing Scrutiny	81
20. Modernization: Knowing the Current Science and Employing Contemporary Technology	82
Conclusion	83
References	84
About the Author	87
<b>4. The Australian System of Quality for Medicines and Other Therapeutic Products</b>	<b>89</b>
<i>Paul K. Priscott</i>	
Introduction	89
The Government System of Healthcare Product Regulation	90
Prescription Medicines	91
Non-Prescription (OTC) Medicines	94
Complementary Medicines	95
Medical Devices, Blood and Tissue Products	96
Regulations Covering the Quality of Healthcare Products	100
The National System in the International Regulatory Environment	103
Value and Purpose of the National Healthcare Product Regulatory System	104
The National Healthcare Product Regulatory Vision for the Future	106
Acknowledgement	107
References	107
About the Author	109
<b>5. Quality Assurance of Healthcare Products in the United Kingdom</b>	<b>111</b>
<i>John L. Turner</i>	
The Government Structures Responsible for the Regulation of the Quality of Healthcare Products in the United Kingdom	111
General	111
Government of the United Kingdom	111
Healthcare Products and Medicinal Products	112
Health and Safety at Work	112
The National Health Service	113
Good Laboratory Practice in Relation to Health and Environmental Safety of Chemical Substances	114
The UK Accreditation Service	114
Commission for Health Improvement	114
Medicinal Products	115

The Licensing Authority	115
The Enforcement Authority	115
The Medicines Commission and Section 4 Committees	116
The British Pharmacopoeia	116
The National Institute for Biological Standards and Control	117
Medicinal Products for Administration to Humans	117
The Medicines and Healthcare products Regulatory Agency	117
The Royal Pharmaceutical Society of Great Britain and Trading Standards Authorities	118
Strategic Health Authorities	118
Medicinal Products for Administration to Animals	118
Medical Devices	119
The Authority and the Committee on Safety of Devices	119
The Medicines and Healthcare products Regulatory Agency	119
Foods and Cosmetics	120
General	120
Foods Standards Agency	120
UK Regulations and Procedures to Ensure the Quality of Healthcare Products	121
Safety of Chemicals used in Healthcare Products and Good Laboratory Practice	121
Medicinal Products	122
General	122
Marketing Authorisation	122
Exemptions from the Requirement for a Marketing Authorisation	124
Medicinal Products Intended for Export	124
Unlicensed 'Special' Medicinal Products	124
Medicinal Products Prepared Under the Supervision of a Pharmacist	125
Herbal Remedies	125
Homoeopathic Medicinal Products	126
Investigational Medicinal Products	126
Manufacture	127
Manufacturer's Licence	127
Manufacture Outside the EC or EEA	127
Mutual Recognition Agreements on Inspection and Authorisation of Manufacturers	128
The 'Qualified Person'	128

Good Manufacturing Practice (GMP)	129
Wholesale Dealing	130
Wholesale Dealer's Licence	130
Wholesale Dealer's (Import) Licence	131
Good Distribution Practice	131
Regulatory Inspection, Testing and Quality	
Surveillance	132
Inspection for Compliance with GMP and GDP	132
Inspection for Compliance with GLP and GCP	133
Medicines Prepared in Pharmacies and Health	
Establishments	133
Official Sampling and Testing of Medicines	133
Suspected Defective Medicines	134
Enforcement of the Medicines Act	135
Medical Devices	135
Foods and Cosmetics	135
The Relationship Between UK Government and Other Organisations	
Involved in the Quality Assurance of Healthcare Products,	
In and Outside the UK	136
UK Organisations	136
General	136
The British Standards Institute and Quality	
Certification Bodies	137
Professional Bodies	138
Academic Institutions	139
Trade Associations	139
The European Community (EC)	139
General	139
Legal Framework	140
Medicinal Products	141
Medical Devices	143
Cosmetics	143
Safety of Chemicals and Good	
Laboratory Practice	143
The European Commission	143
The European Agency for the Evaluation	
of Medicinal Products	144
Wider Europe	145
The European Economic Area	145
The Council of Europe, the European Department	
for the Quality of Medicines and the European	
Pharmacopoeia	145

Protocol to the European Agreement on Conformity Assessment and Acceptance of Industrial Products within the EC and Associated Countries	146
International	146
The World Health Organization	146
Organisation for Economic Cooperation and Development	147
The Pharmaceutical Inspection Convention and Pharmaceutical Cooperation Scheme	147
The Global Harmonisation Taskforce	148
The International Committee on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use	148
Trade and Professional Bodies	148
The Dominant Values in the Regulation of Quality of Healthcare Products in the UK	149
The Vision of Legislation for Quality	149
Author's Comments	150
References	151
Useful Websites	152
United Kingdom: Government/Quasi-Government	152
United Kingdom: Professional and Trade	152
European and International	153
About the Author	154
<b>6. Canada's National Healthcare System of Quality</b>	<b>155</b>
<i>Suzanne Levesque, Pierre Morin and Leonor Ferreira</i>	
Canada's Government Organisation	155
Canada's Quality Regulatory Environment	156
Regulatory Framework	157
Licenses	157
International Conference on Harmonisation	158
Confidentiality	158
The Drug Quality Assessment Program	158
The Food and Drugs Act	159
The Food and Drugs Regulations	160
Posting of Good Manufacturing Practices	161
A Radical but Welcome Evolution	161
Quality Management	161
Quality Assurance	162
Good Manufacturing Practices for Drugs	163
Quality Control	164
Enforcement	166
Values, Integration and Vision	167

Two Basic Values	167
Integration	167
At Last, A Vision	168
Postscript	169
A Business Transformation Initiative	169
Quality is the Key Component	169
About the Authors	170
<b>7. Germany's National Quality System for Healthcare Products</b>	<b>171</b>
<i>Günter Winkmann and Harald G. Schweim</i>	
Part 1: Germany's Government Structure for Regulating Quality	171
Structure: General Remarks	171
Quality of Healthcare Products and Services:	
Definitions and Regulatory Scope	173
Healthcare Products	173
'Quality' – The Idea	174
Healthcare Services	175
The National Quality System for Healthcare Products	176
Medicinal Products and Medical Devices	176
Federal Government Apparatus	176
Laender Governments	179
Quality Assurance of Products and Services	
Provided in Healthcare	180
Part 2: National Regulations covering Quality of	
Healthcare Products	181
Good Laboratory Practice (GLP): German	
Chemicals Act and Derived Administrative	
Provisions	181
Enforcement	183
Medicinal Products Regulations: German Medicines Act	
of 1976 (Law on Trade in Medicinal Products) and	
Derived Ordinances, Legal Specifications and	
Administrative Provisions	183
Purpose	183
Essential Drug Requirements	184
Manufacture	184
Drug Evaluation Prior to Market Approval	185
Drug Testing Instructions	185
Authorization Documents	187
Pharmaceutical Quality and Good Manufacturing	
Practices	190
Quality: AMG Definition	192
Statutory Rules for Operations in	
Pharmaceutical Enterprises	192

Pharmacopoeia	194
Official Collection of Evaluation	
Procedures	195
Quality Documents/Templates from the International Conference on Harmonization and their Adoption	
Status	195
Clinical Trials—Good Clinical Practice	195
National and Supra-National Authorization	
Procedures	199
National Procedures	199
The European Authorisation Procedures for Medicinal Products	204
Distribution of Medicinal Products	207
Special Regulations for Veterinary Medicinal Products	208
Post-Marketing Drug Surveillance Procedures and Pharmacovigilance	208
Procedures to Ensure Appropriate Conformity and Long-Term Quality, Efficacy and Safety	208
Post-Marketing Surveillance	209
Drug Risk Management: Observation, Compilation, Evaluation of Drug Risks and Graduate Management Procedure	210
Pharmacovigilance: National and Supra-National Mutual Information Exchange	214
Electronic Drug Information Systems	216
International Drug Traffic	217
Quality of Conformity Summary—From the Viewpoint of Pharmaceutical Entrepreneurs	217
Regulations	217
Conformity/Quality Management Standards	219
A Concrete, Actual and Somewhat Complex Example: Quality Approach, Licensing and Surveillance of Gene Therapy Medicinal Products	220
Preclinical Research and Development	220
Manufacture	221
Clinical Trials	222
Licensing	224
Probable Future Regulatory Changes	224

Enforcement of AMG Law and PharmBetrV Ordinance	224
Regulations Concerning Narcotics and their Precursors: German Narcotics Act of 1981 and Derived Ordinances, Supplemented by Precursors Control Act of 1994	225
Medical Devices Regulations: German Medical Devices Act and Provisions Derived Thereof	226
Purpose, Definitions, Scope and Responsibilities	227
Quality and its Assessment	229
Legal Classification of Medical Devices According to Potential Risk	229
Notified Bodies	231
CE Marking, Conformity Assessment	232
Harmonized Standards and Common Technical Specifications	233
Conformity Assessment—From the Viewpoint of European and Global Manufacturers	237
Statutory Rules for Operations	239
Registration	240
Biologically Active Medical Devices	240
Mandatory Medical Prescription	240
Clinical Trials	241
Definition of Further National Responsibilities in Context with Quality Assurance	241
Surveillance	242
Procedure and Enforcement	242
Notification of Incidents	243
Risk Management	244
Electronic Information System	247
Enforcement	248
Statutory Quality Assurance in Healthcare	248
The Statutory Sickness Insurance—Social Code, Section V	248
Part 3: Relation of German Governmental Healthcare Quality System to other Systems—Domestic and Supra-National	250
Domestic Systems and Institutions	250
Federal/Laender Authority Level	250
Statutory (Corporatist, Self-governing) Sickness Funds—the GKV	253
Professional Chambers of Care Providers	253
Hospitals/Hospital Societies	254

Laender Health Surveillance Authorities	
Mandating Private Institutions	255
Universities	255
The Association of the Scientific Medical Societies	255
The German Institute for Standardization	256
The German Accreditation Council	257
Private Associations of Health Insurers, Pharmacists, Pharmaceutical and Allied Industries	259
Press/TV and Consumer-protection Associations	260
International Interconnections	261
The Pharmaceutical Inspection Convention	261
The International Conference on Harmonization	264
The Global Harmonization Task Force	265
Bilateral Mutual Recognition Agreements	265
Bilateral MRAs between EU and US, Canada, Switzerland, Australia, New Zealand, Japan	265
MRAs with Central and East European Countries	266
Harmonization of Orphan Medicinal Product Legislation	269
Increasing Role of Pharmacoeconomics	270
Quality Assurance of Healthcare Products and Services ('Technologies') in Other Countries	270
UK: Quality in Pharmacy	272
Netherlands MEB Agency	273
Dominant Values and Underlying Ethical Criteria Associated with the National Quality System in Healthcare	274
Vision of Quality Legislation in Healthcare Manufacturing	275
References	276
Useful Websites	287
Germany (Internet addresses of institutions referred to in this article)	287
European Union, Member States, EEA	
Agreement States	290
International	291
Acknowledgements	292
About the Authors	292

<b>8. Israeli System of Quality: Emphasis on Medicines</b>	<b>295</b>
<i>Karen Ginsbury</i>	
National System of Quality—Governmental Structure	295
Regulation and Enforcement	297
Affiliations and Interactions with Other Organizations	305
The Israel Society for Quality	305
The Standards Institute of Israel	306
The National Physical Laboratory of Israel	306
The National Accreditation Authority	306
Dominant Values and Fundamentals of the Quality System	308
The Vision	308
About the Author	309
<b>9. Japanese National System of Quality: Emphasis on Medicines</b>	<b>311</b>
<i>Kunio Kawamura, Katutoshi Mise and Sadayoshi Tomita</i>	
Concept of Quality Assurance of Pharmaceuticals—	
Revision of Pharmaceutical Affairs Law in Japan	311
Background and History of Revision	311
Need for Legal Framework	311
Safety and Efficacy	312
Risk-based Management for Quality	312
What is Pharmaceutical Quality?	313
Quality Assurance in Japan	313
Definition of Terms Related to Quality According to ISO 9000	314
Regulation of Pharmaceutical Quality and Organization of Industries in Japan—New Regulation Concerning Quality Assurance, Responsibility of Manufacturing and Marketing	314
Newly Revised Pharmaceutical Affairs Law and Related Regulations in Japan	316
Registration Flow of Pharmaceuticals—Development to Approval to Post-marketing Surveillance in Japan	318
Research and Development and New Drug Application Submission	320
New Drug Application and Approval	320
New Drug Investigation, Clinical Trial and Quality Assurance	320
Regulations from the View Points of Ethics and Safety in Development of New Drugs—Consideration of New Drugs and Creature-derived Products	322

Procedures for the Review and Approval of New Drugs, and Measures to Make the Review Processes Faster	322
Drug Master File System for Simpler and Quicker Review Time	322
Good Clinical Practice for the Quality Assurance of Pharmaceuticals Used in Clinical Trials and Higher Quality of Clinical Data	326
Good Manufacturing Practice in Investigational New Drugs	328
Manufacturing, Good Manufacturing Practice	329
GMP in Japan	329
Biological Products and Creature-derived Products	329
Marketing and Post-marketing, Good Vigilance Practice and Good Post-marketing Surveillance	332
Good Vigilance Practice	332
Good Post-marketing Surveillance Practice	332
Safety for Creature-derived Products and Pharmaceuticals	336
Quality and Risk Management Matrix for Creature-derived Pharmaceuticals	336
References	340
About the Authors	341
<b>10. Singapore's National Healthcare System of Quality</b>	<b>343</b>
<i>Teng-Heng Chan and Hesan-Ahmad Quazi</i>	
Introduction	343
General Overview of the Healthcare Delivery System	344
Role of MOH	345
Role of HSA	345
Public Sector/Private Sector	346
Hospitals	346
Key Statistics	346
Government System Responsible for Regulating Quality	347
Ministry of Health (MOH)	347
Clusters—Hospitals and Institutions	349
Health Services Authority (HSA)	350
Professional Centres under HSA	350
Associated Regulations that Cover Healthcare Quality	351
Medicines Act (Chapter 176)	351
Poisons Act (Chapter 234)	353
Private Hospitals and Medical Clinics Act (Chapter 248)	353
The Infectious Diseases Act (Chapter 137)	353
Radiation Protection Act (Chapter 262)	354

Governing Authority and Regulatory Structure	355
Healthcare Services	355
Health-Related Products	355
Licensing Requirements	355
Pharmaceutical Products and Import	
Procedure	355
Product Licensing	356
Import Licensing	357
Wholesale Licensing	357
Manufacturing Licensing	358
Other Licensing Requirement	358
Clinical Drug Trials	359
Environmental Issues	359
Economic and Tax Incentives	359
Import Procedures	360
Quality Control/Quality Assurance	360
Healthcare Professionals	360
Medical Doctors and Traditional Chinese	
Medicine Practitioners	360
Continuous Training of Nurses	362
Quality Assurance for Health-related Products	363
Quality Assurance in Medical and Health	
Laboratories	363
Pharmaceuticals and Health-related Products	364
Evaluation and Registration	364
Pharmaceuticals	364
Complementary Health Products	
(Chinese Proprietary Medicines	
and Health Supplements)	364
Medical Devices	365
Good Manufacturing Practice and Good	
Distribution Practice	365
Product Quality Surveillance	366
Pharmacovigilance and Adverse Drug	
Reactions	367
Advanced Preventive Regulations	368
Forensic Medicine and Science	368
Blood Supply	368
Collection, Processing, Distribution	368
Harmonization of Regulations and Practices in	
Healthcare Products	369
Regional and Global Harmonization Initiatives	369
Harmonization of Pharmaceutical Regulations	369
Harmonization of Cosmetic Regulations	370

Western Pacific Regional Forum for Harmonization of Herbal Medicines	370
Medical Devices Harmonization	370
Asian and Global Harmonization of Medical Devices Regulations	370
Global Harmonization Task Force	370
Regional Harmonization of Radiation Protection Regulations	371
Singapore's National Quality Management System	371
Singapore's National Quality System	371
Quality Management in Hospitals and Healthcare Institutions in Singapore	373
Overview	373
Quality Management Practices in Hospitals	375
Singapore General Hospital	375
Changi General Hospital	376
National University Hospital (NUH)	377
Kandang Kerbau Hospital	377
Private Sector Participation in Quality Management Programs	378
Pharmaceutical Industry in Singapore	379
Governing Legislation	379
Singapore Association of Pharmaceutical Industries	380
Role of the Singapore Association of Pharmaceutical Industries	380
Board of Directors	381
Working Committees	381
International Affiliation	381
Attaining Professional Accreditation And Recognition	382
Accreditation by American Society of Crime Laboratory Directors/Laboratory Accreditation Board	382
Accreditation by Singapore Accreditation Council—Singapore Laboratory Accreditation Scheme	382
Singapore Quality Class	382
Reference Laboratories for the United Nations International Drug Control Programmes	383
Pharmaceutical Inspection Cooperation Scheme	383
Permanent Forum on International Pharmaceutical Training Centre for Radiation Protection	383
Collaboration with the World Health Organization	384
WHO Collaborating Centre for Transfusion Medicine	384

WHO Regional Training Centre for Quality Management Project	384
WHO Collaborating Centre for Food Contamination Monitoring	384
WHO Collaborating Centre for Drug Quality Assurance	384
WHO International Advisory Committee on Electromagnetic Fields	385
WHO Department of Essential Drugs and Medicines Policy	385
WHO International Conference of Drug Regulatory Authorities	385
Summary and Conclusions	385
Acknowledgment	388
Useful Websites	388
References	389
About the Authors	390

## SECTION II: INDUSTRIAL QUALITY SYSTEMATICS: THE INTERPLAY OF QUALITY SYSTEMS IN COMMERCIAL MANUFACTURING

<b>11. Quality Systems and Pharmaceutical cGMP Compliance</b>	<b>395</b>
<i>William S. Hitchings</i>	
Background and History	395
Quality Regulations for Medical Products	397
Quality System Definitions and Framework	398
Medical Product Quality System Development	400
Quality System	401
Management Responsibility	402
Quality Audits	405
Personnel	406
Design Controls	406
Document Controls	408
Purchasing Control	408
Identification and Traceability	409
Production and Process Controls	409
Inspection, Measuring, and Test Equipment	410
Process Validation	411
Receiving/In-process/Finished Product Acceptance	411
Acceptance Status	412
Non-Conforming Product	413
Corrective and Preventative Action	413
Labeling and Packaging Control	414

Handling, Storage and Distribution Records	415
Master Records, Device History Record/Batch Production Record	416
Quality System Records	417
Complaint Files	417
Statistical Procedures	418
Laboratory Controls	418
Summary	419
Systems Approach	419
Bibliography and References	422
About the Author	422
<b>12. Quality Systematics for Contract Service Users</b>	<b>423</b>
<i>Diane M. Petitti</i>	
Introduction	423
Quality Manual	424
Quality Policy	424
Responsibility of Senior Management Team	425
Organization and Responsibility of the Quality Unit	425
Employee Responsibilities	425
Management Review	426
Quality Agreements	426
Quality System Elements	427
The Structure of a Comprehensive Quality System	427
Annual Product Quality Review	428
Audits	429
Batch Disposition	431
Buildings and Facilities	432
Change Control	434
Complaint Handling	435
Contract Service Providers and Consultants	436
Corrective and Preventive Action	437
Deviations	438
Documentation Control	439
Equipment	440
Label and Labeling Control	442
Labeling, Packaging, Storage, Shipping and Distribution	443
Laboratory Control	444
Management and Employee Quality Responsibilities	447
Materials Management and Purchasing Control	448
Production and Process Controls	449
Qualification, Verification and Validation	450
Recalls and Quality Failures	452

Records and Records Retention	453
Returned and Salvaged Goods	455
Specifications	456
Stability	458
Training	459
Conclusion	460
Acknowledgements	461
References	461
About the Author	461
<b>13. Quality for Computerized Systems and Electronic Data in Regulated Environments</b>	<b>463</b>
<i>Teri Stokes</i>	
Introduction	463
Defining Quality for Computerized Systems and Electronic Data	464
Management Control	466
System Reliability	467
Data Integrity and Privacy	471
Auditable Quality	473
Conclusion	476
References	478
About the Author	479
<b>14. Quality Control of Pharmaceutical and Biological Products</b>	<b>481</b>
<i>Effie Michalopoulos</i>	
The Quality Control Laboratory	481
Architecture of Quality Control Laboratory Systems	483
Handling Out of Specification Results	486
Test Methods Development/Validation/Transfer	486
Stability Testing	487
Management and Inventory Control of Laboratory	
Reference Standards	487
Management of Laboratory Reagents	487
Laboratory Sample Management	488
Sample Labeling	488
Rounding of Data and Reporting of Significant Figures	488
Notebook/Worksheet Management and Documentation Practices	
Documentation Practices	489
Calibration and Preventative Maintenance for GMP	
Laboratory Instruments	489
Contract Laboratories	489
Laboratory Training	490
Renovation of Laboratory Facilities	490

Internal Audits	490
The Life Cycle of the Laboratory Systems	491
The Stages of The Life Cycle	496
An Example of a Laboratory Life Cycle Journey	497
Concluding Remarks	506
Acknowledgements	507
References	507
About the Author	509
<b>15. Using Statistics to Measure and Improve Quality</b>	<b>511</b>
<i>Lynn D. Torbeck</i>	
Preface	511
Why Statistics Matter	511
Statistics' Vital Role in Total [Ideal] Quality	512
Training New Staff in Applied Statistics for the Pharmaceutical Industry	513
Introduction	513
History of Statistics	513
Statistical Practice in Pharmaceuticals as Compared to Other Industries	514
Defining Quality	515
Defining Quality for the Pharmaceutical Industry	515
Cost of Quality	516
Statistical Thinking	517
Statistics in Context with Pharmaceutical Quality	518
Simple Statistics Well Used	519
Summarize the Data	520
Plot the Data	520
Inferential Statistics	521
The Role of Statistical Significance Tests	521
Statistical Tools	522
Exploratory Data Analysis	522
The Role of Quality Assurance and Statistics	524
The Role of Quality Control and Statistics	524
The Role of Manufacturing and Statistics	524
Definitions of Quality	525
Quality Control	526
Definition 1	526
Definition 2	526
Quality Assurance	526
Quality Engineering	526
Statistical Quality Control	526
Statistical Process Control	527

Total Quality Management (TQM) or Company-Wide	527
Quality Control	527
Six Sigma	527
Fads in Quality	527
Data Collection	528
Reportable Values	528
Good Data Collection	529
Poor Data Collection	529
Representative <i>versus</i> Random Samples	530
Period Sampling	530
Beginning, Middle and End Sampling	530
Grab Sampling	530
Expert or Judgment Selection	531
Standards versus Specifications	531
Philosophy of Standards <i>versus</i> Specifications	531
USP/NF as a Compendial Standard	531
Specifications	532
Specifications as a Go/No-Go Gauge	534
Reportable Values <i>versus</i> Specifications	535
Setting Specifications	535
Using Historical Data to Set Specifications and Tolerances	535
Out of Specifications	536
Incoming Inspection	537
In-Process Inspection	538
Finished Product Inspection	538
Process Validation	538
Process Control	539
Method Validation	540
Stability Program	541
Annual Review Program and Trending	541
Process Analytical Technologies	542
Resources	543
Software for Statistics	543
Minitab	544
The Excel Dilemma	544
Summary	545
Future Vision	545
References	545
About the Author	551

<b>16. Pharmaceutical Quality Auditing</b>	<b>553</b>
<i>Mary Moriva and Steve Iland</i>	
Introduction	553
Background	554
Considerations in the Design of Quality Audit Programs	557
Requirements for a Quality Audit	557
An Overview of Quality Audit Programs	558
Tiers That Make Up a Company-Wide Audit Program	560
Audit Client	560
First, Second, and Third Party Audits	561
Corporate Quality Audit Programs	562
Intent and Scope	562
Program Deliverables	562
Issues to Manage	563
Division Quality Audit Programs	563
Site (Internal) Quality Audit Programs	564
Intent and Scope	564
Program Deliverables	564
Issues to Manage	565
Coordinating a Company-Wide Quality Audit Program	566
A Range of Approaches that can be used for Quality Auditing	566
Implementing and Managing a Quality Audit Program	568
Selling the Audit Program to Company Management	570
Establishing the Scope of the Audit Program	571
Prioritizing the Audit Schedule	572
Auditors	575
Selecting Auditors	576
Auditors Need Improvement	577
Basic Auditing Skills—Conducting an Audit Interview	578
Auditor Credibility	580
Developing the Program's Team of Auditors	580
Audit Program Policy and Operating Procedures	581
Improving the Audit Program	583
Periodic Audit Program Reporting to Management	583
Performing Quality Audits	584
Planning and Preparation	584
Important Points about the Audit Plan	585
Conducting the Audit	586
Preparing the Draft Audit Report	587
Audit Exit Meeting	588
The Audit Report	589
Areas of Audit Focus when Reviewing Pharmaceutical Quality Systems	589

Key Quality System Aspects to be Reviewed in a Quality Audit of Pharmaceutical Manufacturing	591
Quality System	591
Facilities and Equipment System	592
Materials System	592
Production System	593
Packaging and Labeling System	593
Laboratory Control System	593
Conclusions	598
References	599
Additional Reading	599
About the Authors	600

### SECTION III: PERSPECTIVES ON QUALITY

17. Industrial Quality for the Start-Up Biotech Company	603
<i>Steven S. Kuwahara</i>	
The Real Meaning of Quality	603
Quality is Meeting Specifications	604
Quality is Meeting Customer Requirements	606
Quality is Fitness for Use	609
Quality Before the Customer is Involved	611
Quality from the Viewpoint of the Leaders	613
1. Quality is a Company-Wide Process	614
2. Quality is What the Customer Says it is	615
3. Quality and Cost are a Sum Not a Difference	615
4. Quality Requires Both Individual and Teamwork Zealotry	615
5. Quality is a Way of Management	615
6. Quality and Innovation are Mutually Dependent	616
7. Quality is an Ethic	616
8. Quality Requires Continuous Improvement	616
9. Quality is the Most Effective, Least Capital Intensive Route to Productivity	617
10. Quality is Implemented With a Total System Connected with Customers and Suppliers	617
GMPs	618
Quality from the Manufacturer's Point of View	618
Quality from the Customer's Point of View	620

Competition	621
What Quality Is Not	621
Quality Control, Assurance, and Systems	621
Why Do Things Go Wrong?	625
Dichotomy of Goals	627
Toleration of Deviation	628
Conceptual Problems	629
So What Do We Need To Do?	631
Conclusions About Quality	631
References	632
About the Author	634
<b>18. Quality at the Threshold of Enforcement: Perspectives from Industry and FDA</b>	<b>637</b>
<i>Gregory Bobrowicz</i>	
Dogma and Reality	637
Dogma	637
Reality	638
Scope	638
Evidence	639
FDA Documents Encourage Creative Reading of the Regulation	639
Language of the Different Paradigms	639
Paperwork Without Value	641
Training	641
FDA Inspections	641
Industry Training Programs	642
Conclusion	643
Audits	644
FDA Inspections	644
Industry Audit Programs	644
Conclusion	646
Product Development Reports	647
FDA Inspections	647
Product Development Reports in Industry	647
Conclusion	648
Deviations, Investigations, and CAPA	648
FDA Inspections	648
Deviation Programs in Industry	650
Conclusions	651
Validation	652
FDA Inspections	652
Validation in the Industry	654

Conclusions	655
Other Examples	655
Causes	656
Senior Management is Generally Inexperienced and Uninterested in Quality Except as an Enforcement Risk	656
The Cost of Manufacturing Pharmaceuticals is Irrelevant	657
Enforcement is Spotty and Unpredictable	657
Rules are Known Only by Legend	658
The Words of the Regulations do not Emphasize Effectiveness	659
The FDA is Driven to Avoid Embarrassment and Criticism: Public Health is Only One Piece of This	660
Consequences and Recommendations	661
References	663
About the author	663
<b>19. Training and Learning: Critical Contributors to Quality</b>	<b>665</b>
<i>James L. Vesper</i>	
Introduction	665
Defining Terms	666
Training as an Element of a Quality System	667
Employee Learning and Motivation (25 pts.)	670
Employee Education, Training, and Development	671
Motivation and Career Development	671
Qualitative and Quantitative Measures	672
Training Measures	672
Quality Measures	674
Cost of Quality	675
Integrated Measures	675
The Impact of Training on Quality	676
Training, Learning, and the Quality of the Organization	676
Training and its Connection to Profitability	677
Training and its Connection to Compliance and Organizational Quality	679
They Must Know Something...	679
Training and the Quality of Processes, Products and Services	680
Training on Tasks	681
Training and Investigating Deviations	682
When Training is Not the Answer	685
The Learning Curve	687
Anecdotal Comments from Learners	687
Training and the Quality of Personnel	688
Optimizing Training to Obtain Quality Outcomes	690

Conclusion	693
References	694
About the Author	696
<b>20. Quality Management for Legal/Regulatory Programs</b>	<b>699</b>
<i>Gary Gamerman</i>	
Introduction	699
Quality Management System Elements	700
1. Policy Management	700
2. People and Vendor Management	701
3. Program Management	702
4. Product Management	703
5. Performance Management	703
Conclusion	706
About the Author	707
<b>Index</b>	<b>708</b>